Physician profile
Daniel E Haggstrom
NPI 1891958013
$14,349.84
in general payments reported to CMS, 2019-2025
12 companies · $71.56 in 2025
The $71.56 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $6,660 · 2021: $1,665 · 2022: $99.34 · 2023: $2,477 · 2024: $3,377 · 2025: $71.56.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,905 · Travel and Lodging: $664 · Food and Beverage: $356.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,905.00 |
| Travel and Lodging | $664.04 |
| Food and Beverage | $356.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $8,325.00 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $2,620.02 | 2022-2025 | Opdivo |
| Janssen Biotech, INC. | $1,838.19 | 2024 | Rybrevant |
| Daiichi Sankyo INC. | $1,455.00 | 2024 | |
| Pfizer INC. | $36.00 | 2022 | |
| Novocure INC. | $27.07 | 2025 | |
| Caris Mpi, INC. | $24.99 | 2025 | Mi Cancer Seek |
| Urogen Pharma, INC. | $23.57 | 2024 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Haggstrom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.